Psoriasis: Improving adherence to topical therapy - 24/04/13
International Psoriasis Council
Reprint requests: Peter C. M. van de Kerkhof, MD, PhD, Department of Dermatology, Radboud University Medical Centre Nijmegen, René Descartesdreef 1, 6500 HB Nijmegen, The Netherlands.Résumé |
Topical therapy has an important role in psoriasis treatment. It is efficacious and has a favorable safety profile as demonstrated in clinical trials. However, poor treatment outcomes from topical therapy regimens likely result from poor adherence and ineffective use of the medication. The International Psoriasis Council Topical Therapy Working Group has developed a new model to describe the complex interactions among patient, disease, and treatment characteristics, adherence behavior, and treatment outcomes. Recommendations are provided that may assist the health care provider in encouraging adherent behavior in their patients. By understanding and manipulating the factors that affect treatment adherence, improvement in adherence is possible and hence better control and outcomes in the topical treatment of psoriasis are likely.
Le texte complet de cet article est disponible en PDF.Plan
| Unrestricted funding for this work was provided by Galderma Laboratories, Leo Pharma, Medicis, and Warner Chilcott. These companies had no influence on the content or construction of this review. The Center for Dermatology Research is funded by a grant from Galderma Laboratories LP. |
|
| Disclosure: Dr Feldman has served as a consultant or speaker, or received grant support from, Amgen, Astellas, Centocor, Galderma, Genentech, Photomedex, Steifel, and Warner Chilcott. Dr Horn consults with the International Psoriasis Council. Dr Balkrishnan has served as a consultant for Warner Chilcott and receives grant support from Galderma. Professor Finlay has served as a consultant to Pierre Fabre, Galderma, York Pharma, Leo Laboratories, and Novartis and is a joint copyright holder of the Family Dermatology Life Quality Index. Dr Menter has served as a consultant, investigator, speaker, or advisory board member for Abbott, Amgen, Astellas, Centocor, Galderma, Genentech, Warner Chilcott, and Wyeth. Prof van de Kerkhof has served as a consultant or speaker, or received grant support from, Abbott Laboratories, Allmiral, Barrier Pharmaceutics, Cellgene Inc, Centocor Inc, Leo Pharma, Merck Serono, ScheringPlough, and Wyeth. Drs Basra and McCoy have no conflicts of interest to declare. |
Vol 59 - N° 6
P. 1009-1016 - décembre 2008 Retour au numéro
Article précédent
- Position statement on contemporary issues: Conflict of interest
- Approved by the American Academy of Dermatology Board of Directors, August 2008
- Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review
- Elisabeth B.M. Kroft, Nadine J.G. Berkhof, Peter C.M. van de Kerkhof, Rianne M.J.P. Gerritsen, Elke M.G.J. de Jong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?